ALT, alanine transaminase; AST, aspartate transaminase; AUC, area under the curve; BUN, blood urea nitrogen; CHO, cholesterol; CO2, carbon dioxide; CR, creatinine; Combination therapy; Cu2+, copper ions; DL, drug loading; DLS, dynamic light scattering; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; DOX, doxorubicin; DSPE-PEG2000, 2-distearoyl-snglycero-3-phosphoethanolamine-N-[methyl(polyethylene glycol)-2000; DTT, d,l-dithiothreitol; EDTA, ethylene diamine tetraacetic acid; EE, encapsulation efficacy; FBS, fetal bovine serum; GSH, glutathione; H&E, hematoxylin and eosin; H2O2, hydrogen peroxide; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; HPLC, high-performance liquid chromatography; HSPC, hydrogenated soybean phospholipids; IC50, half maximal inhibitory concentration; IVIS, in vivo imaging system; MLVs, multilamellar vesicles; MRT, mean residence time; MTD, maximum tolerated dose; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Nanoparticles; PBS, phosphate buffer saline; PDI, polydispersity index; PSD LPs, PTX-S-DOX liposomes; PSD NPs, PTX-S-DOX self-assembled nanoparticles; PSD, PTX-S-DOX; PTX, paclitaxel; Paclitaxel­doxorubicin prodrug; Prodrug; ROS, reactive oxygen species; Remote loading liposomes; SD, standard deviation; Safety; TEM, transmission electron microscopy; UV, ultraviolet